PO.EN01.02 · 内分泌肿瘤

ZFX变异在甲状旁腺肿瘤发生中的作用

Role of ZFX variants in parathyroid tumorigenesis

海报缩略图:ZFX变异在甲状旁腺肿瘤发生中的作用
编号 5021 展板 15 时间 4/21 09:00–12:00 区域 Section 33 主讲 Sara Halili, BA
分会场 Signaling Pathways, Metabolism, and Emerging Therapeutic Targets
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Sara Halili, Lucas Iommazzo, Callie Burke, Justin Bellizzi, Jessica Costa-Guda, Andrew Arnold

Center for Molecular Oncology, University of Connecticut School of Medicine, Farmington, CT

摘要 Abstract

中文摘要
ZFX是一种参与干细胞维持和增殖的保守型锌指转录因子,其体细胞改变已在包括子宫内膜样癌、黑色素瘤、急性淋巴细胞白血病和弥漫大B细胞淋巴瘤在内的多种恶性肿瘤中被报道。新出现的证据还将ZFX第12和第13锌指结构域的变异与甲状旁腺肿瘤发生联系起来。甲状旁腺肿瘤会导致钙稳态失调,并增加骨折和肾结石的风险。虽然大多数甲状旁腺肿瘤患者仅有单个腺体受累(约85%),其余15%患有多腺体疾病(MGD)。这种情况以往被称为甲状旁腺增生,具有独特的临床意义,包括较高的复发率以及与遗传综合征(如多发性内分泌腺瘤病1型)的关联,后者可能给家庭成员带来风险。少数研究报道了与MGD相关的ZFX胚系变异;然而,ZFX变异对MGD的贡献仍知之甚少。为评估ZFX变异对MGD的贡献,我们从26例MGD患者的甲状旁腺肿瘤DNA中筛查第12和第13锌指结构域的变异。我们在一份样本中鉴定出p.Arg764Trp变异并确认其为胚系变异。该变异此前曾被报道在甲状旁腺腺瘤中同时作为胚系和体细胞变异,以及在其他恶性肿瘤中作为体细胞变异出现,但尚未在MGD中被报道。我们随后对另一批47例MGD患者的胚系DNA进行了筛查,未在第12和第13锌指结构域的编码序列中发现变异。在该队列中发现p.Arg764Trp变异进一步支持了ZFX变异对MGD的贡献。此类变异使受累患者倾向于罹患MGD而非孤立性甲状旁腺肿瘤的机制值得进一步研究。此外,尽管我们无法获取携带p.Arg764Trp变异患者的家族史,但此前报道的一个携带另一种ZFX变异(p.Tyr774Cys)的三代家系中包括四名被诊断为甲状旁腺功能亢进的女性,其中一名先证者患有MGD。这种家族性模式对ZFX变异患者家庭成员的基因检测和遗传咨询提出了重要的考量。
查看英文原文 English abstract
Somatic alterations in ZFX , a conserved zinc-finger transcription factor involved in stem cell maintenance and proliferation, have been reported across various malignancies including endometrioid carcinoma, melanoma, acute lymphoblastic leukemia, and diffuse large B cell lymphoma. Emerging evidence also links ZFX variants in zinc finger domains 12 and 13 to parathyroid tumorigenesis. Parathyroid gland tumors cause dysregulated calcium homeostasis and increased risk for bone fractures and kidney stones. While most people with parathyroid tumors have only one single gland affected (~85%), the remaining 15% have multigland disease (MGD). This condition, previously known as parathyroid hyperplasia, has distinct clinical implications including higher rates of recurrence and association with genetic syndromes, such as multiple endocrine neoplasia type 1, that may entail risk for family members. A few studies have reported germline variants in ZFX associated with MGD; however, the contribution of ZFX variants in MGD remains poorly understood.To assess the contribution of ZFX variants in MGD, we screened parathyroid tumor DNA from 26 patients with MGD for variants in zinc finger domains 12 and 13. We identified the variant p.Arg764Trp in one sample and confirmed it to be germline. This variant has been previously reported as both germline and somatic in parathyroid adenomas and as a somatic variant in other malignancies, but has not been reported in MGD. We subsequently screened germline DNA from an additional cohort of 47 patients with MGD and found no variants in the coding sequence of zinc finger domains 12 and 13. The finding of the p.Arg764Trp variant in this cohort further supports the contribution of ZFX variants to MGD. The mechanisms by which such variants predispose affected patients for MGD as opposed to solitary parathyroid tumors merit further investigation. Additionally, while we were unable to access family history in the patient with the p.Arg764Trp variant, a previously reported three-generation family with a different ZFX variant (p.Tyr774Cys) included four females diagnosed with hyperparathyroidism, with one proband having MGD. This familial pattern raises important considerations for genetic testing and counseling of family members of patients with ZFX variants.
利益披露 Disclosure
S. Halili, None.. L. Iommazzo, None.. C. Burke, None.. J. Bellizzi, None.. J. Costa-Guda, None.. A. Arnold, None.

← 返回 AACR 2026 检索